Morgan Stanley lowered the firm’s price target on Alcon (ALC) to $84 from $90 and keeps an Equal Weight rating on the shares. The firm continues to like the industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon price target raised to $100 from $99 at BTIG
- Alcon to acquire LumiThera, PBM device
- Alcon price target raised to CHF 101 from CHF 99 at Citi
- Alcon’s Stock Boosted by FDA Approval of Innovative Dry Eye Drug TRYPTYR
- Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target